Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3230156

In Collections

This item can be found in the following collections:

Koziel, M.; Teutsch, C.; Bayer, V.; Lu, S.A.; Gurusamy, V.K.; Halperin, J.L.; ... ; GLORIA-AF Investigators (2021)

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world

Article / Letter to editor
Background: Prescribing patterns for stroke prevention in atrial fibrillation (AF) patients evolved with approval of non-Vitamin K antagonist oral anticoagulants (NOACs) over time.Objectives: To assess changes in anticoagulant prescription patterns in various geographical regions upon first approval of a NOAC and to analyze the evolution of oral anticoagulants (OACs) use over time in relation to CHA(2)DS(2)-VASc and HAS-BLED risk profiles.Methods: Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phases II and III reported data on antithrombotic therapy for patients with newly diagnosed AF and >= 1 stroke risk factor. We focused on sites enrolling patients in both phases and reported treatment patterns for the first 4 years after initial NOAC approval.Results: From GLORIA-AF Phases II and III, 27 432 patients were eligible for this analysis. When contrasting the first year with the fourth year of enrolment, the proportion of...Show moreBackground: Prescribing patterns for stroke prevention in atrial fibrillation (AF) patients evolved with approval of non-Vitamin K antagonist oral anticoagulants (NOACs) over time.Objectives: To assess changes in anticoagulant prescription patterns in various geographical regions upon first approval of a NOAC and to analyze the evolution of oral anticoagulants (OACs) use over time in relation to CHA(2)DS(2)-VASc and HAS-BLED risk profiles.Methods: Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phases II and III reported data on antithrombotic therapy for patients with newly diagnosed AF and >= 1 stroke risk factor. We focused on sites enrolling patients in both phases and reported treatment patterns for the first 4 years after initial NOAC approval.Results: From GLORIA-AF Phases II and III, 27 432 patients were eligible for this analysis. When contrasting the first year with the fourth year of enrolment, the proportion of NOAC prescriptions increased in Asia from 29.2% to 60.8%, in Europe from 53.4% to 75.8%, in North America from 49.0% to 73.9% and in Latin America from 55.7% to 71.1%. The proportion of Vitamin K antagonists (VKAs) use decreased across all regions over time, in Asia from 26.0% to 9.8%, in Europe from 35.5% to 16.8%, in North America from 28.9% to 12.1%, and in Latin America from 32.4% to 17.8%. In the multivariable analysis, factors associated with NOAC prescription were as follows: enrolment year, type of site, region, stroke and bleeding risk scores, and type and categorization of AF.Conclusions: During 4 years after the approval of the first NOAC, NOAC use increased, while VKA use decreased, across all regions.Show less
atrial fibrillation
bleeding risk
GLORIA-AF
oral anticoagulants
stroke risk
All authors
Koziel, M.; Teutsch, C.; Bayer, V.; Lu, S.A.; Gurusamy, V.K.; Halperin, J.L.; Rothman, K.J.; Diener, H.C.; Ma, C.S.; Huisman, M.V.; Lip, G.Y.H.; GLORIA-AF Investigators
Date
2021-07-10
Journal
Journal of Arrhythmia
Volume
37
Issue
4
Pages
990 - 1006
DOI
doi:10.1002/joa3.12588
Link
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/joa3.12588